^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    NT5C (5', 3'-Nucleotidase, Cytosolic)

    i
    Other names: NT5C, 5', 3'-Nucleotidase, Cytosolic, DNT-1, DNT1, 5’ Nucleotidase, Deoxy (Pyrimidine), Cytosolic Type C, 5’(3')-Deoxyribonucleotidase, Cytosolic Type, Uridine 5-Prime Monophosphate Hydrolase 2, Cytosolic 5',3'-Pyrimidine Nucleotidase, Deoxy-5’-Nucleotidase 1, UMPH2, PN-I, CdN, Uridine 5'-Monophosphate Phosphohydrolase 2, Epididymis Secretory Sperm Binding Protein, Epididymis Luminal Protein 74, HEL74, PN-II, P5N2, DNT
    3ms
    Molecular Resonance Quantification and Label-Free Interactome Characterization of Total Proteome of Tumor Specimens Decipher Responder and Success Predictors in Colorectal Cancer Patients Treated With Panitumumab. (PubMed, Cancer Med)
    Combination of PIMS and NPOT coupled to label-free quantitative proteomics point towards the distinct panitumumab mode of action in CRC patients and highlights specific proteins as prognostic biomarkers which need further validation in a bigger cohort and multicentric investigation, ideally involving patient registry follow up data.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • POLD1 (DNA Polymerase Delta 1) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1) • ENO1 (Enolase 1) • YBX1 (Y-Box Binding Protein 1) • CTNND1 (Catenin Delta 1) • ITGB2 (Integrin Subunit Beta 2) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • NT5C (5', 3'-Nucleotidase, Cytosolic) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1) • HSPA4 (Heat Shock Protein Family A (Hsp70) Member 4) • ITGB1 (Integrin Subunit Beta 1) • PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G) • YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta) • HSPA8 (Heat Shock Protein Family A (Hsp70) Member 8) • NCAPD2 (Non-SMC Condensin I Complex Subunit D2)
    |
    Vectibix (panitumumab)
    9ms
    TENT5C functions as a corepressor in the ligand-bound glucocorticoid receptor and estrogen receptor α complexes. (PubMed, FEBS J)
    TENT5C has been proposed to mediate the susceptibility of multiple myeloma to treatment with dexamethasone, a steroid hormone analog that binds to the glucocorticoid receptor (GR)...In addition, the disruption of TENT5C poly(A) polymerase activity does not appear to affect TENT5C repression of ERα in the cell lines studied. Taken together, our findings highlight a role of TENT5C as an NR corepressor, differentially modulating GR- and ERα-induced transcriptional activity.
    Journal
    |
    ER (Estrogen receptor) • NT5C (5', 3'-Nucleotidase, Cytosolic) • TENT5C (Terminal Nucleotidyltransferase 5C)
    |
    dexamethasone
    9ms
    TENT5/FAM46: An Enigmatic Family of Secretory Tuners. (PubMed, Traffic)
    Recently, key roles of TENT5 proteins have been described in cancer, bone homeostasis, immunity, stemness, and fertility. This review will comprehensively analyze the identified cellular functions of this novel family of secretory tuners in physiological and pathological conditions, highlighting the proposed molecular mechanisms and the remaining open questions.
    Review • Journal
    |
    NT5C (5', 3'-Nucleotidase, Cytosolic) • TENT5C (Terminal Nucleotidyltransferase 5C)
    over1year
    5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies (clinicaltrials.gov)
    P1, N=20, Recruiting, Benjamin Tomlinson | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD14 (CD14 Molecule) • DCK (Deoxycytidine Kinase 2) • DNMT1 (DNA methyltransferase 1) • ITGAM (Integrin, alpha M) • NT5C (5', 3'-Nucleotidase, Cytosolic)
    |
    Chr del(5q)
    |
    azacitidine • decitabine
    over1year
    A hot and cold tumor‑related prognostic signature for stage II colorectal cancer. (PubMed, Oncol Lett)
    It was also found that a high-risk score in the eight-gene signature was associated with high immune cell infiltration in patients with CRC. Taken together, these findings revealed some of the differential immune characteristics of hot and cold CRC tumors, and an eight-gene signature prognostic risk model was developed, which may serve as an independent prognostic indicator for patients with stage II CRC (T3-4N0M0).
    Journal • IO biomarker
    |
    IDO1 (Indoleamine 2,3-dioxygenase 1) • NT5C (5', 3'-Nucleotidase, Cytosolic) • MAT1A (Methionine Adenosyltransferase 1A)
    over1year
    Identification and Validation of Nicotinamide Metabolism-Related Gene Signatures as a Novel Prognostic Model for Hepatocellular Carcinoma. (PubMed, Onco Targets Ther)
    Finally, the expression of NAM-related genes and the inhibitory effect of NAM on HCC were verified by experiments. The study first found some Nicotinamide metabolism-related differentially expressed genes (NMRDEGs) that are related to HCC can contribute to predicting survival and monitoring the treatment.
    Journal • Gene Signature
    |
    CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto) • NT5C (5', 3'-Nucleotidase, Cytosolic)
    almost2years
    Expression of DNA Repair Genes in Ewing Sarcoma. (PubMed, Cancer Diagn Progn)
    In addition, low expression of the xrcc4 gene has been associated with better overall survival probability (p=0.032). Our results, even though retrospective and in a small number of patients, highlight the importance of DSBs repair and propose a potential therapeutic target for this type of sarcoma.
    Review • Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51 (RAD51 Homolog A) • EWSR1 (EWS RNA Binding Protein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • RAD52 (RAD52 Homolog DNA Repair Protein) • DRD (DNA Repair Deficiency) • NT5C (5', 3'-Nucleotidase, Cytosolic) • FANCC (FA Complementation Group C)
    |
    DDR • DRD
    2years
    TENT5C/FAM46C modulation in vivo reveals a trade-off between antibody secretion and tumor growth in multiple myeloma. (PubMed, Haematologica)
    Not available.
    Preclinical • Journal
    |
    NT5C (5', 3'-Nucleotidase, Cytosolic) • TENT5C (Terminal Nucleotidyltransferase 5C)
    2years
    Heme Metabolism-Related Gene TENT5C is a Prognostic Marker and Investigating Its Immunological Role in Colon Cancer. (PubMed, Pharmgenomics Pers Med)
    Additionally, TENT5C is associated with both prognosis and immune infiltration. These findings lay a strong groundwork for future research to delve into the specific role of TENT5C in the development and advancement of colorectal cancer.
    Journal
    |
    NT5C (5', 3'-Nucleotidase, Cytosolic) • TENT5C (Terminal Nucleotidyltransferase 5C)
    2years
    Multiplex Detection of Copy Number Alterations in Multiple Myeloma Including Emerging Therapeutic Targets By Digitalmlpa (ASH 2023)
    In addition, this MM assay also gives the possibility to analyze gross CNAs in other hematopoietic neoplasms with overlapping affected regions. Input DNA requirements that are a fraction of current WGS, simple protocol and possibility of combining of digitalMLPA libraries with other NGS libraries make D006 Multiple Myeloma digitalMLPA probemix a reliable, cost-effective and robust method to detect well-established and emerging CNAs.
    IO biomarker
    |
    BRAF (B-raf proto-oncogene) • IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • IRF4 (Interferon regulatory factor 4) • CDKN2C (Cyclin Dependent Kinase Inhibitor 2C) • NT5C (5', 3'-Nucleotidase, Cytosolic) • RPL5 (Ribosomal Protein L5) • TENT5C (Terminal Nucleotidyltransferase 5C) • SLAMF7 (SLAM Family Member 7)
    |
    BRAF V600E • BRAF V600
    over2years
    Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients (ASH 2023)
    "One limitation of the recently presented IRMMa model was an absence of patients prescribed daratumumab-based quadruplet induction, (dara-quads; daratumumab, lenalidomide, dexamethasone with carfilzomib [DKRd] or bortezomib [DVRd]). Among 234 patients analyzed, 86 patients received DKRd and 148 DVRd. Overall median follow-up was 1.4 years (y); 4.2y with DKRd (IQR 1.9-4.7, max 5.7) and 1y with DVRd (IQR 0.5-1.4, max 3.4). 25 patients progressed following DKRd and 20 following DVRd, with 9 progressing during induction chemotherapy."
    Clinical
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • RB1 (RB Transcriptional Corepressor 1) • CDKN2C (Cyclin Dependent Kinase Inhibitor 2C) • NT5C (5', 3'-Nucleotidase, Cytosolic) • RPL5 (Ribosomal Protein L5) • TENT5C (Terminal Nucleotidyltransferase 5C) • XBP1 (X-box-binding protein 1) • FUBP1 (Far Upstream Element Binding Protein 1)
    |
    TP53 mutation • MYC translocation
    |
    MSK-IMPACT • MSK-IMPACT Heme
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • carfilzomib • dexamethasone